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Summary. The role of Sandimmun ~ e o r a l @  (S-n) and 
the immune response in transplant-associated coronary 
vasculopathy (TACV) was evaluated in a Lewis (Lew)- 
to-Fischer-344 (F344) rat abdominal heterotopic heart 
transplant model. Some of the transplant recipients were 
treated with S-n (5mg/kg/day) for  1 4  days post- 
transplant, or until sacrifice. Grafts were subjected to 
immunohistochemical (ED1, CD4, CD8 and a-actin+ 
cells) analysis from day 7 to 100 post-transplant. 
Singenic controls did not develop TACV, irrespective of 
whether they had received the drug or not. TACV was 
detected in Lew-F344 transplants regardless of S-n 
administration with participation of EDl+, CD8+ and a- 
actin+ cells, although its incidence was lower in animals 
receiving prolonged S-n treatment. In this model, 
accelerated arteriosclerosis of the graft appeared to be 
related more to the rejection effect than to the action of 
the immunosuppressive agent. 
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lntroduction 
Coronary vasculopathy, or accelerated arterio- 
sclerosis, is currently the major impediment for the long- 
term survival of a heart transplant recipient. 
This  process is  considered by many to be a 
complication of chronic rejection mediated by the local 
immune response and to require the active participation 
of the cells of the donor vessel wall and recipient 
mononuclear cells,  particularly T lymphocytes, 
macrophages and neutrophils which infiltrate the graft 
(Hruban et al., 1990; Young-Ramsaran et al., 1993; Deng 
et al., 1998). In contrast, other authors suggest that 
coronary disease is  mainly attributable to the 
immunosuppressive agent used in post-transplant 
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therapy. Accordingly, a considerable amount of data 
relates cyclosporin-A (CsA) to the development of 
transplant-associated coronary vasculopathy (TACV) 
(Uretsky et al., 1987; Stamler et al., 1988; Paul et al., 
1994). 
In an attempt to elucidate both the role of the 
immunosuppressive agent and the participation of the 
immune response in the development of TACV, an 
abdominal heterotopic cardiac transplant model in the rat 
was used. The immunosuppressive agent used was 
Sandimmun ~ e o r a l @  (S-n), a water-free microemulsion 
of CsA. To our knowledge, the effects of this new agent 
on the coronary circulation of the transplanted graft have 
not yet been investigated. 
Materials and methods 
Male Lewis (Lew) and Fischer-344 (F344) rats 
weighing 250-300g were employed. Animal care and 
experimental protocols were conducted in compliance 
with EU (European Union) guidelines (EEC-28871- 
22A9 animal care committee). 
Allogenic Lew-to-F344 transplants were performed 
by the Ono and Lindsay technique (Ono and Lindsay, 
1969). The microsurgical procedure and the assessment 
of heterotopic cardiac graft function during the post- 
operative period were conducted as previously described 
(Jurado et al., 1998). Singenic transplants served as 
controls for each strain. 
Experimental design 
The recipient animals were divided into two study 
groups (see Table 1) according to whether or not they 
were administered S-n (5 mg oral dose/Kg,/day). With 
the aim of evaluating any possible long-term (100 days) 
differences attributable to the interruption of treatment, 
group 11 (treated with S-n) was subdivided into: A) 
animals which received the immunosuppressive agent 
from the day of surgery until sacrifice; and B) animals 
administered S-n only during the first 14  days after 
transplant. 
The follow-up times were based on those used in 
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previous investigations (Jurado et al., 1998) which 
showed them to be the most adequate for the short, mid 
and long-term evaluation of the graft. A mean number of 
3 cardiac grafts were obtained at each follow-up time. 
Morphological and ultrastructural analyses 
Morphological and ultrastructural studies were 
performed on specimens of both transplanted and native 
hearts using light and transmission electron microscopy 
respectively. Specimens were obtained by perfusing the 
animals own and transplanted heart with Ringers lactate 
solution. A double approach method was used. First, a 
catheter was introduced into the right jugular vein for the 
administration of 1 m1 sodium heparin (1%) to prevent 
clot formation. Following mid-laparotomy, a second 
catheter was introduced into the inferior vena cava. Once 
the two perfusion systems were opened, a incision in the 
abdominal aorta was performed, to let the preserving 
solution flows. Cardiac grafts were obtained at each 
follow-up time by re-intewention. 
Heart specimens for optical microscopy were fixed 
by immersion in a 10% formo1 solution and embedded in 
paraffin to obtain 5 micron-thick transverse sections. 
Staining was performed using hematoxylin-eosin and 
Massons trichrome stains to obsewation under a ZEISS 
light microscope. 
Recipient animals were prepared for transmission 
electron microscopy by perfusion at 100 mm Hg for 15 
minutes with a 3% glutaraldehyde/l% paraformaldehyde 
(1:2) fixative solution via the inferior vena cava. Cardiac 
grafts were fragmented into small portions, fixed in 3% 
glutaraldehyde for two hours and placed in Millonig 
buffer (pH 7.3). For ultrastructural analysis, these 
specimens were postfixed in 1% osmium tetroxide, 
dehydrated in a graded acetone series and embedded in 
Araldite to obtain thin sections. Finally, the contrast of 
grids was enhanced with lead citrate prior to obsewation 
under a ZEISS 109 transmission electron microscope. 
lmmunohistochemical analysis 
Specimens were fixed and embedded in parafin as 
for  the optical microscopy studies. The  alkaline 
phosphatase-labeled avidin-biotin technique was 
employed using monoclonal antibodies specific for rat 
monocytes/macrophages ED1 (MCA-341, Serotec, 
Oxford, England), human smooth muscle-specific a- 
actin (1A4, A-2547, Sigma, St. Louis, USA) and rat 
lymphocytes CD4, W3125 (CTS 515G, Labgen, 
Barcelona, Spain) and CD8, MRC OX-8 (CTS 418G, 
Labgen, Barcelona, Spain). The protocol consisted of 
incubation with the primary antibody (1:100 in Tris- 
buffered saline; TBS, pH 7.6) for 1 hour at 37 "C, 
incubation with IgG-biotin ( 1 5 0  in TBS) for 45 min, 
and labelling with avidin coupled with alkaline 
phosphatase (1:200 in TBS) for 20 min. These steps took 
place at room temperature. The irnages were developed 
with a chromogenic substrate containing a-naphtol 
phosphate and Fast Red. This step took place at 37 "C. 
Nuclei were counterstained for  5 min with acid 
hematoxylin. 
Assessment of coronary damage 
A morphometric study was performed on 3 0  
transverse 5-micron-thick histological sections 
(including sections from the apex to the upper part of the 
heart) using a computerized image analyser (MICRON). 
Estimation was made of the proportion of coronary 
arteries showing TACV and the degree of participation 
of inflammatory cells (CD4, CD8 and ED1) and smooth 
muscle cells (a-actin+) in the vascular lesion. The 
degree of arteria1 intima1 thickening was scored using a 
scoring system previously described (Adams et al., 
1992), (scale 0-5, 0: normal, to 5: ocluded). Al1 arteries 
seen in each histological section were examined and 
scored. 
Measurements were evaluated by means of a 
descriptive statitistical method to calculate the arithmetic 
mean and standard deviation. The Student-Newman- 
Keuls test for comparison of means was also applied to 
determine the significance of the results obtained at the 
different stages. 
Results 
Hictological results 
Group 1 (untreated transplant recipients) 
A substantial inflammatory response was observed 
Table 1. Study groups. 
GROUP l GROUP ll 
(untreated transplant recipients) (transplant recipients treated with S-n) 
Continuous treatmenta lntenupted treatmentb 
Singenic Transplants (control) --------- Lew-Lew (n=12) Lew-Lew (n=12) Lew-Lew (n=3) 
- -- -- F344-F344 (n=12) F344-F344 (n=12) F344-F344 (n=3) 
Allogenic Transplants Lew-F344 (n=8) - -- -- - -- - Lew-F344 (n-12) Lew-F344 (n=3) 
Study Times failure of the graft 7, 14,50 and 100 days 7,14,50 and 100 days 1 O0 days 
*: from transplant to sacriñce; b: from transplant to day 14 after transplant. 
lmmune response and coronary vasculopathy 
in the singenic transplanted hearts at 14 days. There was 
an abundance of ED1+ cells and a smaller proportion of 
CD8+ cells in the endomyocardium. In contrast, the 
pericardium only harboured weakly stained CD4+ cells 
and a majority of CD8+ lymphocytes. TACV was not 
detected in the vessels of these grafts (Fig. la), although 
in the lumen of some coronary arteries adhered 
mononuclear cells were seen at 14 days post-transplant. 
The infiammatory infiltrate diminished after 50 days. 
The untreated F344 recipients of Lew grafts survived 
50.4I18 days post-transplant. The grafts were infiltrated 
by EDl+, CD4+ and CD8+ cells in the myocardium 
which also showed intense fibrosis. TACV was detected 
in 54.31% of the vessels (Fig. lb). Intima1 hyperplasia 
was concentric and semi-occlusive (large arteries) or 
occlusive (small vessels). 
The native hearts of singenic/allogenic transplant 
recipients showed no vascular changes. 
Fig. l. Morphology of the coronary artery in the transplanted heart 
(Group 1). a. Normal artery in a Lew-to-Lew singenic grafi 50 days after 
transplant. x 500. b. TACV in the vessel of a Lew-to-F344 graft around 
50 days post-transplant. x 630 
Group 11 (transplant recipients treated with S-n) 
Singenic transplant recipients treated with S-n 
showed an increase in interstitial fibrosis and a decrease 
in each of the inflammatory cells under study with 
respect to similar untreated grafts. 
al- - 
Flg. 2. a. a-actin+ cells (red colour) in the neointima (Ne) of a Lew-to- 
F344 graft coronary artery at 100 days post-transplant (interrupted 
treatment). M: medial layer; L: arteria1 lumen. x 400. b. Uneven 
distribution of a-actin+ cells (red colour) in the medial layer (M) and 
neointima (Ne) of a Lew-to-F344 graft coronary aitery at 100 days post- 
transplant (continuous S-n treatment). Arrows: interna1 elastic lamina; L: 
lmmune response and coronary vasculopathy 
When the immunosuppressive treatment was 
interrupted at 14 days, obse~at ions  made in the Lew-to- 
F344 grafts were similar to those recorded in group 1. 
Transplanted hearts showed necrosis, tissue destruction 
and intense myocardial fibrosis at 1 0 0  days. The 
Flg. 3. Lew-to-F344 graíts (interrupted treatment). a. An epicardiac 
vessel with stenosis surrounded by ED1+ cells (red colour) may be 
observed. A few of these cells may also be seen in the lumen cell mass 
(arrows). M: medial layer. x 200. b. CD8+ lymphocytes (arrows) 
insideloutside a small occluded vessel. x 630 
Flg. 4. Coronary artery of a Lew-to-F344 graít at 100 days post-implant 
(continuous S-n treatment) showing several layers of both secretory 
smooth muscle cells (Ssmc) and other cell types p) over the interna1 
elastic lamina (IEL). Mx: extracellular rnatrix; E: endothelium. A few 
Ssmc migrate towards the neointima through a fenestration (arrow) in 
the IEL. x 3,000 
lrnmune response and coronary vasculopathy 
endocardial inflammatory infiltrate was rich in, ED1+ 
and CD8+ cells. Some CD4+ lymphocytes were seen to 
infiltrate via small capillaries and appeared as weakly 
stained cells in the pericardium. Severa1 arteries 
examined in the transplanted heart developed TACV, 
with the participation of a-actin+ (Fig. 2a), ED1+ and a 
scarce number of CD8+ cells (Fig. 3). An ED1+ 
macrophage periadventitial barrier was detected around 
affected coronary arteries (Fig. 3a). 
The allogenic Lew-to-F344 grafts in the continuous 
S-n treatment group showed intense adhesion and 
infiltration of ED1+ cells at 14 days both in the arteria1 
wall and in the myocardium. CD8+ and scarce CD4+ 
cells were detected between cardiac fibres and in the 
pericardium. Some of the arteries examined in the 
transplanted heart developed TACV. From 50-100 days 
post-transplant, the number of affected vessels increased, 
although large arteries showed non-occlusive intima1 
thickening (TACV) in the shape of a half-moon 
comprised of severa1 cell layers. Many of these cells 
showed secretory characteristics and were a-actin+ 
(Figs. 2b, 4). At 100 days, only a few of the pericardial 
cells were CD8+ and CD4+ and a few labelled 
macrophages could still be seen in the endocardium. 
The native hearts of singenic transplant recipients 
showed no vascular changes. The arteries of the native 
hearts (in both treatment groups) showed (at 100 days) 
Table 2. Evaluation of coronary damage (TACV) in Lew-to-F344 grafts. 
an intact endothelium under which the elastic lamina 
was of a fibrous appearance with no loss in thickness. 
An enlarged extracellular matrix was seen in the media1 
layer. 
Histopathological analysis 
The results of the morphometric study are shown in 
Tables 2 and 3. TACV was shown by 54.31% of the 
arteries in Lew grafts transplanted into F344 recipients 
receiving no immunosuppressive treatment and by 
61.63% of the arteries in Lew-F344 grafts receiving 
interrupted treatment. However, when the treatment 
received by the Lew graft recipients was prolonged, the 
incidence of TACV fe11 by 12.63% at 100 days with 
respect to the interrupted treatment (p>0.01, no 
statistical significance), and by 26.96% at around 50 
days with respect to the untreated recipients (Student- 
Newman-Keuls test pc0.01). A predominance of 
macrophages (EDl+) was obsewed before 50 days in the 
neointima while in the long-term (100 days), a-actin+ 
cells were the major cell type in this layer (Student- 
Newman-Keuls test ps.01). A low proportion of CD8+ 
lymphocytes was detected in affected vessels at each 
follow-up time and in each group. CD4+ celis were only 
seen in the myocardial inflammatory infiltrate. A 
continuous decrease in the number of a-actin+ cells in 
Study times (days) Affected arteriesa (%) Luminal occlusionb (%) Average lesion grade 
Wihout treatment 
Continuous treatment 
50.411 8 
7 
14 
50 
100 
lnterrupted treatment 1 O0 
-- 
a: ffected arteries; b: occluded arteries with respect to the total arteries seen. The Student-Newman-Keuls test showed statistical signiflcance (ps 0.01) 
in theses cases: *, vs "without treatment"; +, vs "100 days in the same group (continuous treatment)'. The rest of the comparisons did not show 
statistical significance (p>0.01). 
Table 3. lmmunohistochemical analysis of affected arteries by TACV in Lew-to-F344 allografts. 
Study times (days) a-actin (%) ED1 (%) CD8 (%) 
Medial layer lntimai layer Medial layer Intima1 layer Medial layer Intirnal layer 
Without treatment 
Continuous treatment 
50.4118 56.1 317.03 15.9415.06 10.0713.54 21.3515.00 3.3311 .O0 7.79I2.47 
7 100.0010.00 0.2510.05 3.0611 .O7 65.4013.41" 0.40M.02 7.4211 -87 
14 95.3012.05 2.3010.25 12.0013.45 79.9012.P 0.2810.01 5.2312.05 
50 70.0015.45 20.0617.02 5.0012.50 30.0511.76 0.5010.52 6.3513.62 
1 O0 53.8213.80+ 40.3013.95*, 6.3812.38 12.7012.40a 0.5210.07 6.0714.00 
lnterrupted treatrnent 1 O0 43.5917.08 42.4413.09* 6.21 11 .06 9.9212.05 0.96i0.30 11.1 616.65 
The Student-Newman-Keuls test showed statistical significance (p 0.01) in theses cases: +, vs "a-actin+ cells in media at 7, 14 and 50 days in 
continuous treatment"; 0, vs "a-actin+ cells in hyperplasia at 7, 14 and 50 days in continuous treatmenr; *, vs "ED1+ cells in hyperplasia in the same 
group and stage'; *, vs 'a-actin+ cells in hyperplasia in the same group and stage", and a,vs 'ED1+ cells in hyperplasia at 7 and 14 days in continuous 
treatment". 
lmmune response and coronary vasculopathy 
arteries showing TACV was recorded in the media1 layer 
(Student-Newman-Keuls test p5 0.01). 
Arteria1 sections from singenic grafts showed minor 
alterations by 10% (Lew-to-Lew) and by 15% (F344-to- 
F344) (average lesion grade 0.12) in groups 1 and 11. 
Discussion 
Cardiac transplant is presently considered the sole 
therapeutic measure for a series of terminal cardio- 
pathies. The allotransplant experimental model is the 
closest to clinical heart transplant inducing substantial 
changes in the coronary circulation. In such a model, the 
physiological reparative process is interfered with by the 
immunological rejection of the grafted organ and by the 
immunosuppressive treatment. 
Acute rejection has been largely overcome by the 
use of immunosuppressive agents and chronic rejection 
has emerged as the main cause of graft failure (Adams 
and Tilney, 1989). The most significant pathological 
finding in the latter process is the diffuse, concentric 
intimal proliferation incurred by large and medium 
calibre arteries (Billingham, 1992). Heart transplants are 
particularly sensitive to these vascular changes (Nitkin et 
al., 1985) and the appearance of TACV is the main 
determining factor for the survival of the heart transplant 
patient (Jamieson, 1992; Schroeder et al., 1992). 
It has been proposed that accelerated arteriosclerosis 
in heart transplant recipients is a complication of 
rejection mediated by the immune response. The process 
has been associated with an accumulation of 
macrophages, lymphocytes and smooth muscle cells in 
the coronary vessel intima and with endothelial lesions 
provoked by cytotoxic T lymphocytes (CD8+) (Hruban 
et al., 1990; Young-Ramsaran et al., 1993; Deng et al., 
1998). 
Lew-to-F344 cardiac grafts undergo similar chronic 
rejection and arteriosclerotic lesioning to that produced 
in humans (Adams et al., 1992) and are considered a 
useful experimental model. TACV in Lew-to-F344 
cardiac allografts develops in stages: before 30 days 
there is a predominance of ED1+ macrophages in the 
neointima accompanied by a small disperse population 
of T lymphocytes (CD4+ and CD8+); from 30 to 90 
days, a-act in+ smooth muscle cells appear in the 
neointima, and from 90 days onwards these cells are the 
predominant type in this layer (Cramer et al., 1992; 
Adams et al., 1993; Russell et al., 1995). 
Although the findings of several investigations 
confirm the existence of transplant arteriosclerosis 
before the introduction of CsA (Thomson, 1969; Bieber 
et al., 1970; Kosek et al., 1971), some authors (Paul et 
al., 1992, 1994) have demonstrated an atherogenic effect 
of the agent even in s ingenic transplant models.  
However, other authors propose that CsA has a 
protective effect and have shown that treatment with 
CsA at adequate doses can reduce intimal thickness and 
cellular filtration in TACV (Cramer et al., 1990; Meiser 
et al., 1991; Handa et al., 1993; De Caterina et al., 1995; 
Koskinen et al., 1995). 
On the other hand, there are known side effects of 
S-n, such as hypercholesterolemia, hypertension and 
diabetes (Van Buren et al., 1998; Trull et al., 1999) 
which could contribute to vasculopathy. However, the 
direct effects of S-n on coronary vessels after transplant 
are unknown, although in an aortic transplant model, this 
agent was responsible for the same regression in intimal 
hyperplasia at half the dose with respect to other 
formulations of the drug (Little et al., 1996). 
CsA could perform its protective role by interfering 
with the normal functioning of cooperating T cells 
(mainly CD4+) thus inhibiting the growth and 
proliferation of T lymphocytes and the activation of T 
cells and macrophages. It has been shown that CsA is 
only efficient during the initial phases of the immune 
response and is useful in the prophylaxis of acute 
rejection but not in the treatment of the immune reaction 
(Homan et al., 1980; Morris et al., 1985). 
In the present singenic (control) recipients, TACV 
did not develop whether the recipients were treated with 
S-n or not. However, when Lew-to-F344 grafts were 
performed, graft vasculopathy was detected irrespective 
of the immunosuppressive treatment with participation 
of E D l + ,  CD8+ and a-act in+ cells. However, the 
incidence of TACV was somewhat lower in the case of 
prolonged treatment. Animals undergoing transplant 
develop TACV despite immunosuppressive treatment 
since, once sensitised by an extremely scarce number of 
CD4+ T cells (escaping the action of the CsA) or pre- 
sensitised by graft antigens, the CD8+ T cells are able to 
act on the target organ. 
It may be concluded that in the present study, S-n 
reduces the severity of the lesion (TACV) when 
produced. Graft-accelerated arteriosclerosis, at least in 
this experimental model, seems to be related more to the 
rejection effect than to the action of the immuno- 
suppressive drug. 
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